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Reports from neural cell cultures and experimental animal studies provide evidence of
age- and disease-related changes in retrograde transport of spent or misfolded proteins
destined for degradation or recycling. However, few studies address these issues in
human brain from those who either age without dementia and overt neuropathology,
or succumb to Alzheimer’s; especially as such propensity may be influenced by APOE
genotype.We studied the expression and distribution of the dynein subunit dynactin-P50,
the β amyloid precursor protein (βAPP), and hyperphosphorylated tau (P-tau) in tissues
and tissue sections of brains from non-demented, neuropathology-free patients and
from Alzheimer patients, with either APOE ε3,3 or APOE ε4,4. We found that advanced
age in patients without dementia or neuropathological change was associated with
coordinated increases in dynactin-P50 and βAPP in neurons in pyramidal layers of the
hippocampus. In contrast, in Alzheimer’s, βAPP and dynactin were significantly reduced.
Furthermore, the dynactin-P50 and βAPP that was present was located primarily in
dystrophic neurites in Aβ plaques. Tissues from Alzheimer patients with APOE ε3,3
had less P-tau, more βAPP, dynactin-P50, and synaptophysin than did tissues from
Alzheimer patients carrying APOE ε4,4. It is logical to conclude, then, that as neurons
age successfully, there is coordination between retrograde delivery and maintenance
and repair, as well as between retrograde delivery and degradation and/or recycling of
spent proteins. The buildup of proteins slated for repair, synaptic viability, transport, and
re-cycling in neuron soma and dystrophic neurites suggest a loss of this coordination in
Alzheimer neurons. Inheritance of APOE ε3,3 rather than APOE ε4,4, is associated with
neuronal resilience, suggestive of better repair capabilities, more synapses, more efficient
transport, and less hyperphosphorylation of tau. We conclude that even in disease the
ε3 allele is neuroprotective.
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Introduction
Fast-axonal transport is an essential part of normal neuronal
function (Paschal and Vallee, 1987; Brady, 1991), and transport
failures manifest as a dying-back of axons from the synapse to the
neuronal soma, a phenomena that occurs prior to the neuronal
loss characteristic of Alzheimer’s disease (AD) (Kanaan et al.,
2013). The retrograde transport complex dynein is a large multi-
subunit complex, which attaches to its cargo by the dynactin-P50
subunit (Chen et al., 2014). Dynein-mediated transport is spec-
ulated to be mostly regulated by the dynactin complex (Stokin
and Goldstein, 2006). The active dynein complex is important
in alignment of microtubules and is, at least partially, respon-
sible for the growth of microtubules into the growth cone of
axons (Ahmad et al., 2006). These functions suggest that dynein
is needed for neuronal survival, especially for the survival of
those neurons with long axons that function to connect CNS
neuronal somas with distant targets in the periphery (Ebneth
et al., 1998; Heerssen et al., 2004). Further, dynein-mediated
axonal transport depends on interactions between neurotrophic
factors, their receptors, and the dynein complex. For example,
decreased brain-derived neurotropic factor (BDNF) is associated
with decreased retrograde transport (Heerssen et al., 2004).
Among the endosomes transported by dynein, many con-
tain Aβ or βAPP; the latter being expressed in response to neu-
ronal stress imposed by neural injury (Rosen et al., 1989; Kimura
et al., 2009). Elevated expression of βAPP is a neuronal response
believed to be neuroprotective (Masliah et al., 1997) based on
findings in mice deficient in βAPP; such mice display deficits in
long term potentiation and memory (Dawson et al., 1999). Nor-
mal transport of excess βAPP and Aβ to the soma for degradation
is necessary to terminate reactions, which over timemay facilitate
Aβ deposition. For example, as a result of breakdown in endo-
some transport, Aβ vesicles in the cell build up, causing further
neuronal stress, further increases in βAPP production, and inhi-
bition of Aβ reuptake and processing, leading to Aβ deposition
(Kimura et al., 2009). Such deposition has been noted in neurons
adjacent to Aβ plaques, and is characterized by a failure to mount
appropriate neuronal acute phase responses such as elevation of
βAPP (Barger et al., 2008).
The genesis and stability of microtubules is dependent
on appropriately phosphorylated tau, a principal microtubule-
associated protein that is necessary for genesis and stability of
the microtubule tracks that are used in intracellular transport
(Yoon et al., 2008) and in maintenance of the unipolarity of the
axon, which is important for dynein and kinesin motor func-
tions (Ebneth et al., 1998). Tau is normally distributed along the
axon in a decreasing gradient, with low tau concentration near
the cell body, and higher concentrations near the axonal end-
ing, for appropriate attachment of motor proteins (Dixit et al.,
2008). In the absence of regulation, there is neuritic beading,
axonal swelling, and bulbous neurites, which is presumably due
to stearic hindrance or microtubule dysfunction in the areas of
the swelling (Tan et al., 2007; Kimura et al., 2009). With either
broken tracks or an obstacle in its path, tau begins to build up in
the soma, which may result from, or may lead to, its hyperphos-
phorylation and ultimately formation of neurofibrillary tangles
(NFTs) in cell bodies and apical dendrites, in distal dendrites as
neuropil threads, as well as in the enlarged dystrophic neurites in
Aβ plaques (Gotz et al., 2006).
Several studies dating back to as early as 1967 suggest that
microtubule-dependent transport is impaired in Alzheimer’s dis-
ease (Suzuki and Terry, 1967) (for review see Stokin and Gold-
stein, 2006). The correlation between neurofibrillary tangles and
dementia severity (Gotz et al., 2006) may be related to abnormal
phosphorylation of tau and resultant changes in axonal transport
of hyperphosphorylated tau and βAPP, as well as other cellular
entities (Greenberg and Kosik, 1995). For instance, the presence
in axons and neurites of abnormal swellings containing neurofib-
rillary tangles, phagocytic elements, and mitochondria (Pilling
et al., 2006; Tan et al., 2007) suggests that motor protein dys-
function and/or microtubule loss (Cash et al., 2003) contribute
to these anomalies. This is of considerable interest as failures
in endosomal functions that are dependent on retrograde trans-
port by the dynein system leave the neuron unable to rid itself
of unwanted or misfolded proteins, and spent organelles. It is
also important to note that in both Alzheimer’s and Down’s syn-
drome, endosomal changes are among the earliest pathological
anomalies (Cataldo et al., 1996, 2003), suggesting that failures in
this system are particularly powerful as they occur early and are
persistent, with middle and end stage accumulation of unwanted
proteins in synaptic areas.
The role of APOE genotype in risk for development of
Alzheimer’s is well known (Saunders et al., 1993; Strittmatter
et al., 1993; LaDu et al., 1994; Weisgraber andMahley, 1996), and
the potential additive effect of havingAPOE ε4 allele(s) on the risk
for developing Alzheimer’s in risk-conferring neurological condi-
tions such as in head trauma (Nicoll et al., 1995; Reinvang et al.,
2013) and in temporal lobe epilepsy (Mackenzie andMiller, 1994;
Gouras et al., 1997; Aboud et al., 2012, 2013) has been reported.
APOE genotype has also been shown to impact age-associated
cognitive status (Vemuri et al., 2010, 2014) and is associated with
vocabulary loss with age (Baxter et al., 2003), especially in the
context of more limited education and less intellectual stimula-
tion (Bunce et al., 2014). Only recently has it been suggested that
inheritance of specific APOE genotypes may be more related to
the ability of one genotype to confer neuronal resilience rather
than neurodegeneration; that is, allelic combinations without ε4
are more resilient than combinations with ε4 (Caesar and Gandy,
2012).
To assess whether age and/or Alzheimer’s and APOE geno-
type are related to changes in neuronal and tissue levels of
the neuronal acute phase response protein βAPP, the retro-
grade microtubule motor protein dynactin-P50, accumulation of
hyperphosphorylated tau in NFTs, or synaptic loss (as denoted
by a reduction in the synaptic marker synaptophysin), human
brain tissue samples and tissue sections from brains of cog-
nitively intact patients at different ages (age-matched control,
or AMC), and from Alzheimer patients were immunoreacted
with antibodies that specifically recognize dynactin-P50, βAPP,
synaptophysin, and hyperphosphorylation sites on the tau in
neurofibrillary tangles. Dynactin-P50 expression in neurons in
both hippocampal dentate gyrus and pyramidal neuron areas
increased with normal aging, while such expression in Alzheimer
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patients was markedly less. Similarly, the expression of βAPP was
elevated with aging, but not with Alzheimer’s. Disease-associated
decreases in neuronal βAPP and dynactin-P50 expression were
accompanied by an accumulation of βAPP, dynactin-P50, and
neurofibrillary tangles in neuron somas and dystrophic neuritic
compartments, especially in neuritic plaques. The relative levels
of βAPP, dynactin-P50, and synaptophysin were higher in tissue
from APOE ε3,3 carriers than in APOE ε4,4 carriers, while the




Hippocampal tissues from 23 brains obtained at autopsy from
11 neurologically normal individuals (AMC, ages 16–81 years,
all APOE ε3,3) and 12 Alzheimer patients (ages 68–90 years; 4
APOE ε3,4 and 8 APOE ε3,3) were used for immunohistochem-
ical analysis of cellular expression of dynactin-P50, βAPP, and
hyperphosphorylated tau. To assess the potential role of APOE
ε3,3 vs. APOE ε4,4 in dynactin-P50 and dynein/cargo interac-
tions, hippocampal tissue from 11 Alzheimer patients (5 APOE
ε3,3 and 6 APOE ε4,4) and 4 APOE ε3,3 neurologically normal
controls was evaluated with respect to the relative tissue levels
of dynactin-p50, hyperphosphorylated tau, and synaptophysin.
All tissues were neuropathologically evaluated and the diagnoses
of AD or AMC were made according to National Institute of
Aging-Reagan guidelines1 .
Fluorescent Immunohistochemistry
As described in a previous study (Barger et al., 2008), paraffin
was removed in xylene from 7µm paraffin-embedded tissue sec-
tions and rehydrated in graduated ethanol solutions to deionized
water. Sections were incubated in 3% H2O2in 97% methanol for
30min at room temperature and washed 3 times with PBS. For
βAPP, dynactin P-50, and AT8 labeling, tissue sections were pre-
treated by boiling in 1mmol/L of EDTA (pH 8.0) for 10min
at medium power in a microwave oven. After 3 rinses in PBS,
all sections were blocked in 80% Dulbecco’s Modified Eagle’s
Medium [DMEM], 19% fetal calf serum, 1% bovine serum albu-
min for 1 h at room temperature. After PBS rinses, sections were
incubated with primary antibody solutions overnight at room
temperature: mouse anti-dynactin P-50 (1:1000) (BD Bioscience,
San Jose, CA), mouse anti-βAPP (1:100) (Zymed, Grand Island,
NY), and mouse anti-hyperphosphorylated tau (AT8) (1:2000)
(Thermo Scientific, Pittsburg, PA). After PBS rinses, a pre-diluted
horse anti-mouse immunoglobulin G conjugated to peroxidase
(Vector, Burlingame, CA) was further diluted 1:5 for detection of
dynactin P-50, hyperphosphorylated tau (AT8), and βAPP pri-
mary antibodies. Development of the immunofluorescent sig-
nal was achieved by signal amplification with Alexa Fluor 350,
488, and 594 tyramide (Molecular Probes, Eugene, OR), using
11997. Consensus recommendations for the postmortem diagnosis of Alzheimer’s
disease. The National Institute on Aging, and Reagan Institute Working Group on
Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease.
Neurobiol. Aging 18, S1–S2.
the manufacturer’s recommended conditions. Before the addi-
tion of the second or third primary antibody in double and triple
labeling experiments, slides were rinsed in PBS, incubated in
0.01 N HCl for 10min at room temperature to inactivate per-
oxidase, rinsed again in PBS, and subjected to antigen-specific
pretreatments as necessary. Previous to secondary antibody
application, lipofuscin staining was blocked by pretreatment
with Sudan Black B dissolved in 80% ethanol (Sigma, St.
Louis, MO). Tissue sections were counterstained with 100 ng/ml
4′,6 diamino-2-phenylindole dihydrochloride (DAPI, Invitrogen,
Grand Island, NY) for 5min at room temperature to visualize
nuclei. To prevent fading of immunofluorescence, the tissue sec-
tions weremounted with Vectashieldmountingmedium (Vector,
Burlingame, CA).
In this study, we use “expression” to mean fluorescence inten-
sity. The fluorescence intensity of βAPP, dynactin, and p-tau in
immunoreacted tissues were examined according to standardized
laboratory practices using a Nikon Eclipse E600 microscope with
a Y-FL epifluorescence attachment (Barger et al., 2008; Aboud
et al., 2012, 2013). A CoolSNAP ES digital camera (Roper Sci-
entific, Ottobrunn, Germany) was used to capture images from
the hippocampus, and the parahippocampal gyrus at 20× or
40× magnification under identical conditions (exposure times).
Thresholding and total fluorescence intensity calculations were
derived from gray-scale images (Figure 1)—captured using NIS-
Elements BR3 (Nikon.com) andMetaVue 6.2r2 software (Molec-
ular Devices, Sunnyvale, CA) at a minimum threshold range
of 300 and 600 for dynactin P-50 and βAPP—in neurons, i.e.,
cells with nuclear diameters greater than 8µm and in neurites,
i.e., plaque-associated, non-nucleated immunoreactive entities
(Figure 1).
In brief, quantification protocols were as follows: initial image
samples were taken for each patient to determine optimal expo-
sure times, such that all signal was clearly detected and no pix-
els were saturated. Once exposure time was determined, images
from all slides were taken at the same exposure time, with mul-
tiple images taken in areas of interest in each sample. NIS-
Elements software denotes pixel saturation, and fields containing
such saturation due to blood vessels or other artifacts were
excluded from data collection and calculation. Intensity calcula-
tions are averaged for each individual, with the average intensity
considered as a single data point for statistical analysis.
Duolink Proximity Ligation Assay
Duolink PLA kits were purchased from Sigma, and were used
according to manufacturer’s protocols. In brief, slides were
treated similar to immunofluorescent protocols above, with
the replacement of fluorescent antibodies with oligonucleotide-
conjugated secondary antibodies (termed PLUS and MINUS)
that are complementary and form a circular nucleotide sequence
if the two secondary antibodies are within 40 nm distance from
each other. Slides are treated with a ligase following the sec-
ondary antibodies, and then a fluorescent signal is produced by
rolling circle elongation from the circular DNA strand formed
from the PLUS and MINUS antibodies. Duolink was performed
with the dynactin-P50 and AT8 primary antibodies listed
above.
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FIGURE 1 | Examples of immunofluorescent images used in
neuritic plaque color overlays and for grayscale quantification.
Separate channel images were taken and overlaid, and colocalization
was assessed based on color combinations, e.g., Red + Green =
Yellow. Red represents hyperphosphorylated tau (AT8) and green
represents dynactin-P50 (DynP50).
Western Immunoblot Analysis
Proteins were extracted from tissue with a lysis buffer comprised
of 50mM Tris-HCl (pH 7.5), 150mM NaCl, 1% Nonidet P40,
0.5% sodium deoxycholate and 0.1% SDS; lysates were quanti-
fied using a Micro BCA assay reagent kit (Pierce, Rockford IL) as
described previously (Li et al., 1998). Aliquots (100µg each) were
loaded onto 10% SDS-polyacrylamide gels, subjected to elec-
trophoresis at 70V for 20min and 90V for 1.5 h, and transferred
to nitrocellulose membranes. Membrane blots were blocked in I-
Block Buffer (Applied Biosystem Inc., Bedford, MA) for 45min,
then incubated overnight separately at 4◦Cwith primary antibod-
ies to: P-tau (AT8, 1:1000); dynactin-P50 (1:1000); synaptophysin
1:1000; or actin (1:5000), incubated for 1 h at room temperature
with alkaline phosphatase-conjugated secondary antibody, and
developed using the Western-Light™ Chemiluminescent Detec-
tion System (Applied Biosystem Inc., Bedford MA). Autoradio-
graphs were digitized and analyzed using NIH ImageJ software,
version 1.60. Results are reported as steady-state levels, relative to
actin.
Statistical Analysis
Group differences were determined byWilcoxon-Mann-Whitney
Rank Sum Test for significance, with two tails and α = 0.05.
Results are expressed as mean± SEM.
Results
βAPP and Dynactin-P50 Expression Increased
with Age
Due to the elongated morphology of neurons and their unique
functions, precise and timely delivery of specific proteins and
organelles by motor proteins must be tightly maintained. In
particular, retrograde transport of spent proteins or damaged
organelles is very important and is predicted to change with age,
as oxidative and inflammatory stresses accumulate with the wear
and tear of time. To investigate this prediction, we ask a simple
question: Are there changes in the expression of the regulatory
cargo attachment protein dynactin-p50 and its cargo βAPP with
increasing age in the absence of disease? Dynactin-P50 fluores-
cent intensity (expression) was noticeably elevated with increas-
ing age, from teenage to the eighth decade, in pyramidal neurons
in hippocampal tissue sections from neurologically and neu-
ropathologically normal individuals (Figures 2A,B). This age-
related increase in dynactin-P50 expression was accompanied by
an increase in βAPP expression in neuronal somas and neuronal
processes (Figures 2A,C), suggesting that in response to the nor-
mal wear and tear of time, βAPP and dynactin expression are
increased for membrane repair and transport of cellular entities.
βAPP and Dynactin-P50 Expression is Diminished
in Alzheimer Hippocampus
In order to assess the effect of AD on the amount of βAPP and
dynactin-p50 in the neurons of those with Alzheimer’s disease,
separate from the effect of normal aging, we selected cases with
Alzheimer’s disease, and compared them to control individuals
that matched them closely in age (AMCs were within 1 year of
their AD counterparts, with the total age range for both groups
between 69 and 80). We found that there was a dramatic decrease
in dynactin-P50 expression in analogous neurons in Alzheimer
patients (Figures 3A,B). This decrease is suggestive of the idea
that in AD, neurons are unable to transport proteins to the soma
for degradation and recycling, perhaps accounting, at least in
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FIGURE 2 | Age-related changes in expression of dynactinP-50
(DynP50) and β-amyloid precursor protein (βAPP). Dynactin-P50
and βAPP were detected by immunofluorescence in tissue sections
from hippocampus at the level of the lateral geniculate nucleus from
6 neurologically normal individuals across an age span of 16–80
years. (A) Representative immunofluorescent images from the six
individuals; blue represents DAPI staining of cellular DNA, red
represents dynactinP-50, green represents βAPP, and yellow
represents colocalization of dynactinP-50 and βAPP. Images were
digitized at 20× magnification. Scale bar = 20µm. Quantitation of
dynactinP-50 (B) and βAPP (C) immunofluorescence intensity was
obtained by thresholding gray-scale images and integrating pixels as
described in Materials and Methods section. Values reflect the mean
of 6 images per specimen.
part, for the deleterious downstream consequences of a build-up
of misfolded proteins and potentially-neurotoxic aggregates. The
decrease in dynactin-P50 expression in neurons in tissue from
Alzheimer patients, compared to that in tissue from age-matched
neurologically normal individuals, was accompanied by a simi-
larly marked decrease in neuronal βAPP (Figures 4A,B) and in
βAPP mRNA, as we previously reported (Barger et al., 2008).
Dynactin, βAPP, and Neurofibrillary Tangles are
Colocalized and Distributed throughout Neurons
in Alzheimer’s
In neurologically normal individuals, the increased expression
of dynactin-P50 and βAPP associated with advancing age was
apparent in the soma and in the axon hillock of both dentate and
pyramidal neurons (Figure 5, 1st row). In contrast, in Alzheimer
tissue from analogous regions of hippocampus, the expression
of dynactin-P50 and βAPP was dramatically reduced in dentate
and pyramidal neurons (Figure 5, 2nd and 3rd row). Moreover,
in dynactin-P50 and βAPP-immunoreactive neurons that also
contained neurofibrillary tangles, there was an apparent prefer-
ential redistribution of all three antigens from neuronal somas
to neuritic bulbous terminals (Figure 5, neuron soma, white
arrows; anuclear neurites, yellow arrows). Large tangle-bearing
pyramidal neurons were also noted to contain both βAPP and
dynactin-P50. In fact, P-tau immunoreactive tangles, βAPP, and
dynactin-P50 appear to be trapped in both soma and neurites
(Figure 5, red arrows), which may be due, at least in part, to dis-
ruption of the entire (anterograde and retrograde) microtubule
motor system, asmight be inferred from previous studies demon-
strating that endosomal transport and processing are disrupted
in Down’s syndrome and in Alzheimer’s disease (Cataldo et al.,
1996). To determine proximity of P-tau and dynactin-p50, we
probed tissue with the Duolink Proximity Ligation Assay (PLA).
This assay produces a fluorescent signal if two immunogens are
within 40 nm distance by using complementary DNA strands on
antibody probes with subsequent ligation and detection. In this
way, we showed that dynactin-P50 and P-tau are indeed located
within 40 nm of each other in neuritic plaques in AD (Figure 5B),
strongly suggesting aggregation.
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FIGURE 3 | Comparison of dynactin-P50 (DynP50) expression
between neurologically normal controls (AMC) and Alzheimer (AD)
patients. (A) DynactinP-50 (green) in tissue sections from the
hippocampal cell layer. Images were digitized at 20× magnification. Blue
represents DAPI staining of cellular DNA. (B) Quantification of DynP50 in
AD (n = 4) vs. neurologically normal control (AMC, n = 4). Values reflect
the mean of 30 images of the pyramidal cell layer for AD and AMC.
Significance determined by Wilcoxon-Mann-Whitney Rank Sum Test, with
*denoting p ≤ 0.05. Data reported as group mean with error bars
denoting SEM.
Hyperphosphorylated Tau is Increased, and
Dynactin-P50 and Synaptophysin are Decreased
in APOE ε4,4 Alzheimer Patients Compared to
ε3,3
Marked differences in fluorescence intensity were noted in AD
patients depending on their APOE genotype. Those with ε3,3
genotypes had overall higher dynactin-P50 levels and lower P-
Tau levels compared to their ε4,4 counterparts (Figures 6A,B,
representative images, Figure 6C, fluorescence quantification).
This was confirmed in Western blot: relative to actin steady-
state levels, overall, the expression of hyperphosphorylated
tau is higher in Alzheimer patients with APOE ε4,4 than in
patients with APOE ε3,3, while dynactin and synaptophysin were
lower (Figures 6D,E). As synaptophysin is commonly used as a
marker for healthy functional synapses, this implies a connec-
tion between APOE genotype, retrograde transport, and synaptic
integrity. Interestingly, in comparing the right-most lanes in the
Alzheimer ε3,3 and ε4,4 western blot (Figure 6E, gray boxes), the
hyperphosphorylated tau, synaptophysin, and dynactin-P50 lev-
els are almost identical, perhaps explained by risk factors other
than APOE genotype.
Discussion
It is clear that successful brain aging, that is, aging free of demen-
tia and of Alzheimer neuropathology at autopsy, is possible as
many people live to old age without dementia (Evans et al., 1989;
Paganini-Hill et al., 2015). This suggests that in successful aging,
the brain meets the challenges of stresses that come with aging by
bringing into play mechanisms that are necessary to maintain the
status quo in a neuron. Such maintenance requires appropriate
regulation (i.e., synthesis and activation) of proteins involved in
the following: maintenance of membranes (e.g., βAPP); micro-
tubule stability (e.g., tau); anterograde transport of proteins to
where they are needed (via kinesin); retrograde transport of spent
proteins and organelles (via dynein); and proper degradation
and processing of spent proteins (ubiquitination for proteosta-
sis). Numerous cell culture and experimental animal research
studies have shown age-related changes in neuronal functions,
many of which involve molecular mechanisms of neuronal trans-
port systems. Our aim here was to define and characterize retro-
grade transport protein levels that accompany successful aging,
and how those that aged successfully differed from those with
Alzheimer’s disease. We note here that in successful aging, there
is a coordinated increase in dynactin and βAPP with advancing
age. In contrast, many of the changes we discuss in successful
aging may not occur in those with Alzheimer’s disease, such that
less βAPP and dynactin are produced in those with AD com-
pared to their age-matched counterparts, and that the dynactin
and APP which is produced is trapped in aggregates with hyper-
phosphorylated tau. Further, these deleterious effects are exac-
erbated by inheritance of APOE ε4,4 alleles in comparison to
inheritance of APOE ε3,3. Our data is consistent with the idea
that Alzheimer’s disease constitutes a failure of neurons to sustain
the levels of βAPP and dynactin-P50 necessary for the increased
demands imposed by aging, especially in combination with other
risk factors such as inheritance of APOE ε4.
Normal Aging
We focused on βAPP because it is the acute phase response
protein in neurons (Barger et al., 2008) and is of particular
importance in Alzheimer pathogenesis; and on dynein, in partic-
ular dynactin-P50, the cargo-binding protein of dynein, because
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FIGURE 4 | βAPP levels are reduced in Alzheimer’s (AD), and
dynactin-P50 (DynP50) and βAPP localization is disrupted.
Dynactin-P50 (green) and βAPP (red) were detected by immunofluorescence
in tissue sections from hippocampus. (A) Total APP intensity is decreased in
AD cases. Blue represents DAPI staining of cellular DNA. Images were
digitized at 40× magnification. Scale bar = 10µm. (B) Overall βAPP
fluorescence intensity is diminished in AD compared to neurologically normal
controls (AMC). Significance determined by Wilcoxon-Mann-Whitney Rank
Sum Test, with *denoting p ≤ 0.05. Data reported as group mean with error
bars denoting SEM.
βAPP is a prominent cargo for retrograde transport (Gunawar-
dena et al., 2013). As we are interested in age-related effects, we
restricted our cohort to patients without dementia and without
neuropathology at autopsy. In our sample, we show that βAPP
expression increases with age, and that this increase is accompa-
nied by an increase in dynactin-P50. This is consistent with the
idea that aging stress induces increased βAPP production, and
that this increased βAPP necessitates a concomitant increase in
transport proteins, as illustrated with dynactin-P50 in our study.
Other studies have also pointed to differential expression of this
system depending on age. Age-related increases in specific iso-
forms and fragments of βAPP (133 and 19 kDa, respectively)
have been reported to occur with advancing age (Nordstedt et al.,
1991), while decreases in microtubule density, the “tracks” upon
which dynein complexes travel, are also occurring in an age-
relatedmanner (Cash et al., 2003). In 2007, Kimura et al. reported
yet another effect, this time in aged monkeys: with increased
age, the interaction between the dynein intermediate chain and
dynactin was reduced, possibly due to phosphorylation state,
and leading to decreased retrograde transport efficiency (Kimura
et al., 2007). All of these effects may be responsible for possibly
compensatory increases in dynactin we report here. We feel that
it should be stressed here that individuals used in this study, even
of advanced age, did not have disease, and the implication therein
is that age alone is not sufficient to lead to neuropathology, as
long as compensatory mechanisms function correctly.
βAPP and Dynactin in Alzheimer’s Disease
The story is different in individuals with neurodegenerative dis-
ease. Axonal transport disturbances are important factors in sev-
eral neurological disorders, including Parkinson’s disease (Chu
et al., 2012) and amyotrophic lateral sclerosis (Ikenaka et al.,
2012). Similar disturbances in axonal transport have been sug-
gested to occur in Alzheimer’s disease, based on the dystrophic
appearance of axons and their bulbous neurites and dendrites in
Alzheimer brain (Stokin and Goldstein, 2006). These characteris-
tic defects in AD are suggestive of defects in axonal transport and
have been widely reported on by many groups (Heerssen et al.,
2004; Ahmad et al., 2006; Kimura et al., 2009). Our finding of
dramatic reductions in neuronal dynein expression in Alzheimer
brain, relative to that in neurologically normal controls of similar
age (AMC), provides necessary support for the early suggestion
by Terry (1998) that motor protein abnormalities are principal
factors in synaptic pathology. Although this Alzheimer-related
reduction in dynactin-P50 that we show relative to that in AMC is
unlikely to be the only contributor to neuronal dysfunction, it is
likely to be an important component of the endosomal-lysosomal
system dysfunction that is related to defects in βAPP process-
ing in AD (i.e., autophagy) (Cataldo et al., 1996), and in Down’s
(Cataldo et al., 2000). It may be the case that such transport pro-
tein dysfunction is secondary to primary lysosomal defects: Lee
et al. demonstrated that lysosomal dysfunction was sufficient to
cause axonal transport deficits of the like seen in Alzheimer’s
disease (Lee et al., 2011).
Neurofibrillary Tangles
The co-localization of dynein and βAPP as well as dynein
and hyperphosphorylated tau in Alzheimer disease is consis-
tent with the idea that—unlike the state of affairs in aged
controls—spent or misfolded proteins, that would otherwise be
transported back to the soma for degradation or recycling, are
sequestered in aggregates in neurites and in somas. The presence
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FIGURE 5 | Dynactin-P50 (DynP50), βAPP, and hyperphosphorylated
tau in neurofibrillary tangles (NFT) localization in AD and
neurologically normal controls (AMC). (A) Dynactin-P50 (red), βAPP
(green), and NFT (blue) were detected by immunofluorescence in
hippocampal tissue of AD and neurologically normal individuals (AMC). In
AMC (top row), note the absence of neurofibrillary tangles, and increased
dynactin-P50 and βAPP compared to AD (middle and bottom rows).
Further, DynP50 and βAPP appear brighter in somas of AMC vs. somas
of AD without NFTs (white arrows). Dynactin-P50, APP, and NFT
immunoreactivity was observed in anuclear bulbous neurites (yellow
arrows). AD somas containing NFTs showed the highest immunoreactivity
in AD for dynactin-P50, and βAPP, implying possible aggregation of all
three antigens (red arrows). (B) Duolink proximity ligation assay (PLA)
detects immunogens within 40 nm distance in tissue sections. Image
shows neuritic plaque enriched with dynactin-P50 and P-tau in close
proximity.
of the retrogrademotor protein dynactin-P50 in these aggregates,
together with the fact that less dynactin-P50 is present overall
in Alzheimer brain, supports a prominent role for retrograde
transport dysfunction in Alzheimer pathogenesis. Moreover, the
Alzheimer-related changes in dynein expression and distribution
reported here, together with the sequestering of abnormal pro-
teins in somas and terminals may contribute to the synaptic loss
in AD that Terry and Katzman suggest is related to decreases in
cognition and increased risk for precocious development of AD
(Terry and Katzman, 2001).
The early finding of the importance of tau in the genesis and
stabilization of microtubules (Black et al., 1986) has implications
for our study in that the hyperphosphorylation of tau and subse-
quent formation of neurofibrillary tangles suggests sequestration
of hyperphosphorylated tau in such tangles may decrease the
amount of tau available for its normal functions to promote pro-
duction of microtubule associated proteins for genesis and sta-
bility of microtubules (Trojanowski and Lee, 2005). This, along
with the reported decrease in microtubule density with increas-
ing age (Cash et al., 2003), the weakened synthesis of dynein, and
the paucity of non-aggregated dynactin-P50 in Alzheimer neuron
somas that we show here, suggest that in Alzheimer’s, disrup-
tion in synthesis of transport proteins necessary for cellular and
synaptic maintenance and repair leads to failures in proteostasis,
synaptic loss, and neuronal dysfunction and death. While there is
still no firmly established relationship between Aβ plaques and
the presence and distribution of neurofibrillary tangles within
neurons in Alzheimer’s (Armstrong et al., 1993), our finding of
both βAPP and dynactin-P50 in neurofibrillary tangle-laden bul-
bous neurites in plaques as well as in plaque-adjacent neuron
somas suggests that plaques and plaque proximity may con-
tribute to retrograde transport dysfunction and therefore to the
buildup, rather than the degradation, of toxic aggregates such as
hyperphosphorylated tau. Indeed, in Alzheimer’s disease, increas-
ing plaque complexity (diffuse to diffuse neuritic to dense-core
neuritic) is associated with more βAPP-immunoreactive neurites
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FIGURE 6 | Comparison of tissue levels of dynactin-P50 (DynP50),
P-tau, and synaptophysin (Syn) in Alzheimer patients with APOE ε3,3
vs. ε4,4. (A) Dynactin-P50 (green) was less in AD patients with APOE ε4,4,
than in those with ε3,3, while (B) P-tau was increased in ε4,4. Representative
images. (C) Fluorescence intensity quantification of P-tau and dynactin-P50
levels in AD patients with ε3,3 vs. ε4,4. (D) Steady state protein levels,
relative to that of actin, of P-tau in Alzheimer patients with ε3,3 were lower
than levels in those with ε4,4, while synaptophysin and dynactin-P50 levels
were higher in ε3,3 compared with ε4,4. (E) Western blot comparison of
protein levels in AD vs. Control, and between AD ε3,3 vs. AD ε4,4. Actin was
used as loading control. Lanes in gray boxes demonstrate a patient with
APOE ε3,3 genotype with similar levels of proteins to those in a patient with
APOE ε4,4 genotype, suggestive of the possible presence of Alzheimer risk
factors aside from APOE genotype. Wilcoxon-Mann-Whitney Rank Sum Test
was used for statistical significance, with *denoting p ≤ 0.05 and **denoting
p ≤ 0.01. Data reported as group mean with error bars denoting SEM.
and more activated astrocytes overexpressing S100B (Mrak et al.,
1996), which could further exacerbate neuronal transport deficits,
through its promotion of βAPP synthesis and neurite outgrowth
and its dose-dependent induction of microtubule associated pro-
tein 2 (Li et al., 1998).
APOE genotype
We present evidence here that APOE genotype has a part in the
pathogenesis of these transport deficits. Our findings show that
the tissue levels of dynactin-P50 and synaptophysin are lower
in Alzheimer patients with APOE ε4,4 compared to APOE ε3,3,
while hyperphosphorylated tau is elevated, suggesting that inher-
itance of ε3,3 confers a measure of neuronal resilience, even in
the presence of Alzheimer’s disease. Our findings regarding the
influence of APOE genotype on the steady state levels of the
motor protein dynactin-P50 and one of its potential cargoes,
hyperphosphorylated tau, suggests that, compared to carriers of
APOE ε3,3, carriers ofAPOE ε4,4 are at increased risk of excessive
aggregation in neuronal soma and dystrophic neurites of spent
and misfolded proteins. Therefore, these aggregated proteins are
not available to proteosomes or lysosomes for degradation or
re-cycling.
It is important to note that possession of APOE ε3,3 geno-
type alone does not protect against disease-associated risk factors
that themselves increase hyperphosphorylated tau. It does appear
that as hyperphosphorylated tau increases above some level in
carriers of APOE ε3,3 with disease, there is not a corresponding
increase in motor proteins. Moreover, APOE ε3,3 carriers who
have hyperphosphorylated tau levels similar to carriers of APOE
ε4,4 also have levels of synaptophysin that are similar to those
of ε4,4 carriers. The association between high hyperphosphory-
lated tau, low dynactin-P50, and synaptic loss, as denoted by low
synaptophysin levels noted in one of our ε3,3 cases, suggests that
factors other than APOE genotype are involved in aggregate for-
mation, and may separately contribute to retrograde transport
deficits. It is interesting to note that elevation of IL-1β, the bell-
wether of Alzheimer’s neuroinflammation, increases synthesis of
MAPKp38 and production of its active phosphorylated form, viz.,
the form of MAPKp38 that we found necessary for production
of hyperphosphorylated tau and for the reduction of synthesis of
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synaptophysin (Li et al., 2003). In view of this, in the many con-
ditions in which IL-1β levels are elevated, it is logical to predict
a corresponding increase in production of hyperphosphorylated
tau and a decrease in production of synaptophysin, regardless of
APOE genotype.
Conclusion
Age imposes increasing amounts of neural stress, even in a per-
son free of dementia and of neuropathological change. This stress
is mitigated in neurons by increasing the levels of the neuronal
stress response protein βAPP and its retrograde transport protein
dynactin-P50, allowing for retrograde transport of βAPP, which
after use, may need to be re-cycled or degraded. However, in
Alzheimer’s, a combination of factors, including APOE genotype,
disrupts this stress response system beyond its ability to cope, and
in this way, initiates and perpetuates a cycle in which Aβ is gener-
ated, and tau hyperphosphorylation and aggregation are favored.
These proteins may then stick together, and sequester useful pro-
teins such as dynactin-P50 into aggregates, preventing them from
performing their function; this deleterious cycle leads to synaptic
loss, and eventually cell death. In addition to the risk factors we
mention here, namely,APOE genotype, other reports imply other
factors can come into play, specifically endosome/lysosome dys-
function (Kimura et al., 2009; Lee et al., 2011), microtubule den-
sity reduction (Cash et al., 2003), and decreased dynein/dynactin
interaction (Kimura et al., 2007), leading to decreased transport
efficiency. This idea points to the possibility of targeting the pro-
tein transport system in development of Alzheimer treatments, in
addition to its important regulators: inflammation, proteostasis,
and stress-response.
Our findings suggest that neurodegenerative events seen
in Alzheimer’s are related to dysregulation of microtubule-
associated motors that carry proteins and other cargo to and
from the neuronal soma, causing an accumulation of dynactin-
P50, βAPP, and neurofibrillary tangles in the bulbous neurite
endings present in the neuritic amyloid plaques diagnostic of
Alzheimer’s disease. The fact that each of these entities is also
present in neuronal somas, especially those adjacent to plaques,
suggests that not only retrograde but also anterograde motor sys-
tems are impacted in Alzheimer pathogenesis. Our finding that
even in disease APOE ε3,3 plays an ameliorating role in poten-
tial for delivery of spent and misfolded proteins may explain,
at least in part, the benefits of inheriting this genotype on risk
of development of Alzheimer’s. Importantly, our findings make
clear the possibility of successful aging characterized by necessary
changes in transport measures to meet age-related challenges,
such as changes in the expression of cargo entities associated with
age-appropriate expression of proteins, organelles, and neuro-
transmitters.
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